Credit deterioration in portfolio companies
Repayment depends on borrower sales, royalties, and operating performance.
- Scope
- Finance receivables and royalty assets
- Materiality
- high
SWK Holdings Corp
SWK Holdings Corp is a U.S.-based specialty finance company that provides asset-backed lending and royalty financing to healthcare and life sciences businesses. Its portfolio includes senior secured debt, revenue-interest financings, royalty purchases, and related investment positions, with operations organized around finance receivables and pharmaceutical development.
49,0 %
−6,1 %
−7,8 %
9.41
9.41
| % | |
|---|---|
| Finance Receivables | 80% Senior secured loans and revenue-interest assets repaid from borrower cash flows, net sales, or royalties. |
| Royalty Purchases | 10% Purchased royalty streams tied to licensed pharmaceutical and medical technology products. |
| Pharmaceutical Development | 5% Development-stage pharmaceutical assets and related manufacturing or R&D activities. |
| Marketable Investments and Warrants | 5% Minority investments, warrant assets, and other equity-linked positions in portfolio companies. |
SWK primarily finances healthcare, pharmaceutical, and medical technology companies that need non-dilutive capital tied...
- Healthcare and life sciences borrowersprimary
Companies that borrow against product revenues, royalties, or other secured assets to fund operations and growth.
- Royalty sellers and licensorsprimary
Owners of pharmaceutical or medical product royalty streams that sell future cash flows for upfront capital.
- Medical technology and specialty pharma counterpartiessecondary
Businesses whose product sales generate the revenue interests and royalties that support SWK's assets.
- Equity and warrant counterpartiessecondary
Portfolio companies where SWK holds warrants or equity-linked positions alongside debt or royalty assets.
SWK is headquartered in the United States and its portfolio is primarily tied to U.S. healthcare and life sciences...
- •Headquartered in the United States
- •Portfolio concentrated in U.S. healthcare and life sciences
- •Some royalty exposure to international sales
- •No country-level revenue split disclosed in excerpts
- •Geography affects borrower sales and royalty collections
SWK's strategy centers on originating structured healthcare financings and royalty assets that generate contractual...
01
Expand structured healthcare lendingmedium-term
This is the core source of contractual cash flow and portfolio growth.
02
Grow royalty and revenue-interest assetsmedium-term
Royalty streams diversify returns beyond traditional lending and can provide long-duration cash flows.
03
Actively manage portfolio exits and monetizationsshort-term
Payoffs, sales, and conversions recycle capital and reduce concentration in aging positions.
SWK is exposed to credit risk, borrower performance risk, and valuation risk because its assets are repaid from...
Interest-rate and funding spread risk
Borrowing costs can rise faster than asset yields on floating/fixed mix portfolios.
- Scope
- Revolving credit facility and leveraged investments
- Materiality
- high
Concentration in healthcare and life sciences assets
A small number of specialized counterparties can drive a large share of returns.
- Scope
- Royalty purchases and secured loans
- Materiality
- high
Fair value volatility on investments and warrants
Market and company-specific changes affect unrealized gains/losses and carrying values.
- Scope
- Warrant assets, marketable investments, impaired positions
- Materiality
- medium
Inflation pressure on partner companies
Higher input costs can reduce borrower profitability and repayment capacity.
- Scope
- Portfolio companies with limited pricing power
- Materiality
- medium
Fair value measurement
Can create unrealized gains or losses and change net asset value
Revenue recognition on royalties and revenue interests
Can cause uneven quarterly revenue and comparability issues
Non-accrual and impairment
Directly affects interest income and asset carrying values
Held-for-sale accounting
Changes balance sheet mix and can affect reported revenue timing
: 29.4.2026